{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:42:06Z","timestamp":1767825726447,"version":"3.49.0"},"reference-count":53,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T00:00:00Z","timestamp":1396569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In primary cutaneous B\u2010cell lymphomas (<jats:styled-content style=\"fixed-case\">PCBCL<\/jats:styled-content>), radiotherapy \u2013 or surgery in a minority of cases \u2013 is the first\u2010line treatment in follicle center lymphoma (<jats:styled-content style=\"fixed-case\">PCFCL<\/jats:styled-content>) and marginal zone B\u2010cell lymphoma (<jats:styled-content style=\"fixed-case\">PCMZL<\/jats:styled-content>). Conversely, patients with multifocal skin involvement or relapsed\/refractory disease deserve a systemic chemotherapy. In diffuse large B\u2010cell lymphoma, leg type (<jats:styled-content style=\"fixed-case\">PCLBCL\u2010LT<\/jats:styled-content>), due its poorer outcome, cyclophosphamide, doxorubicin, vincristine, and prednisone (<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>)\u2010like regimens are the most commonly used frontline, although hard to propose in elderly patients. In this regard, the association of rituximab (<jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>) and pegylated liposomal doxorubicin (<jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content>) can be considered a promising, alternative approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Based on the favorable results reported with R and <jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content> in several recent trials, we decided to test efficacy and safety of this combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twelve patients with <jats:styled-content style=\"fixed-case\">PCBCL<\/jats:styled-content> were treated with R plus <jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content>, and 7 had relapsed disease. Treatment plan consisted of 2 monthly cycles of R 375\u00a0mg\/m<jats:sup>2<\/jats:sup> and <jats:styled-content style=\"fixed-case\">PLD<\/jats:styled-content> 20\u00a0mg\/m<jats:sup>2<\/jats:sup> day 1;15, followed (in responders) by two cycles given only at day 1. All patients received prophylactic pyridoxine to prevent palmar\u2010plantar erythrodysesthesia (<jats:styled-content style=\"fixed-case\">PPE<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten of 12 patients had a response (eight complete; two partial), remarkably 2\/3 with <jats:styled-content style=\"fixed-case\">PCLBCL\u2010LT<\/jats:styled-content>. Two patients did not respond (one progressive disease, <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>, and one stable disease). Three patients died after a median follow\u2010up of 56\u00a0months, two patients due to <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>, and 1 due to a second neoplasm. Two out of 10 responders relapsed after 31 and 32\u00a0months, respectively. Hematological toxicity was negligible (one case of grade 2 neutropenia), as well as extra\u2010hematological toxicity (two cases of grade 2 <jats:styled-content style=\"fixed-case\">PPE<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These preliminary data suggest that R\u2010PLD is effective and well tolerated in all subsets of <jats:styled-content style=\"fixed-case\">PCBCL<\/jats:styled-content> and may be offered frontline in indolent cases unsuitable for radiotherapy or surgery as well as in more aggressive cases with contraindications to <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>\u2010like regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12315","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T04:53:12Z","timestamp":1395031992000},"page":"129-136","source":"Crossref","is-referenced-by-count":24,"title":["Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B\u2010cell lymphomas"],"prefix":"10.1111","volume":"93","author":[{"given":"Alberto","family":"Fabbri","sequence":"first","affiliation":[{"name":"Division of Haematology University Hospital of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Alterini","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Florence Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Rubegni","sequence":"additional","affiliation":[{"name":"Division of Dermatology University Hospital of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Florence Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Delfino","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Surgery and Translational Medicine University of Florence Medical School and Health District Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Florence Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Fimiani","sequence":"additional","affiliation":[{"name":"Division of Dermatology University Hospital of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Florence Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Division of Haematology University Hospital of Siena Siena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Surgery and Translational Medicine University of Florence Medical School and Health District Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Gruppo Italiano Linfomi Cutanei (GILC)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"e_1_2_8_3_1","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze R","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07852_suppl.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_8_6_1","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S","year":"2008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2009.09.003"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.059"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890350042008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3602"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152850"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1520"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.9.1139"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)70068-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500399698"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07523.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00720.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06659.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12484"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn636"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809057618"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6285"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.093"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.043"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02488.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-200006000-00009"},{"key":"e_1_2_8_28_1","first-page":"753","article-title":"Rituximab for primary cutaneous diffuse large B\u2010cell lymphoma","volume":"20","author":"Fenot M","year":"2010","journal-title":"Eur J Dermatol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.001"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.053413"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.Supplement-1.94"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.004"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:1:55"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11593"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06682.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10879"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01197.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059469"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.12.1475"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23360"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900308"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.044"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6396"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8065"},{"key":"e_1_2_8_50_1","first-page":"33","article-title":"Anti\u2010CD20 antibody (IDEC\u2010C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12315","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:08:22Z","timestamp":1695550102000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/ejh.12315"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12315","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,4]]}}}